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Abstract 
     The cannabinoid system is a novel intercellular 
signaling system that plays a prominent role, among 
others, in the control of basal ganglia function. This 
finding can be concluded from the data obtained 
in different series of anatomical, biochemical, 
electrophysiological and pharmacological studies. 
These  data  demonstrated:  (i)  that  the basal ganglia 
contain high levels of endocannabinoids and their 
receptors, mainly including the cannabinoid CB1
receptor  subtype  but     also a related receptor type, the
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vanilloid TRPV1 receptor; (ii) that the activation or the blockade of this system 
produces important changes in motor behavior, changes that are originated as 
a consequence of interactions of the cannabinoid system with various classic 
neurotransmitters such as GABA, dopamine or glutamate; and (iii) the 
occurrence of marked changes in specific elements of the cannabinoid 
signaling system in various basal ganglia disorders, with emphasis in the 
induction/upregulation of the cannabinoid CB2 receptor subtype. This large 
evidence relating endocannabinoids and their receptors to the function of the 
basal ganglia, both in the healthy and the pathological brain, has provided 
support for the idea that cannabinoid-based medicines, with selectivity for 
different targets of the cannabinoid signaling system (synthetic enzymes, 
receptors, inactivation system), might have therapeutic potential to alleviate 
symptoms and/or provide neuroprotection in basal ganglia disorders, in 
particular Parkinson´s disease and Huntington´s chorea. The present chapter 
will review the knowledge on this issue trying to establish the future lines for 
the research on the therapeutic potential of the cannabinoid signaling system 
in basal ganglia disorders. 
 
Introduction: Brief summary of the cannabinoid 
signaling system 
 The great increase experienced in the research on cannabinoids and 
related-molecules during the last years can be directly related to the discovery 
of the so-called “endogenous cannabinoid system”, a new intercellular 
communication system that is mostly active in the central and peripheral 
nervous system [1]. The cannabinoid system is made up of a family of 
endogenous arachidonic acid derivatives called “endocannabinoids” that act 
through at least two types of G protein-coupled receptors, termed cannabinoid 
CB1 and CB2 receptors [2]. These receptors are also activated by different 
compounds present in the plant Cannabis sativa that are called 
phytocannabinoids. The action of endocannabinoids at their receptors 
terminates in an endogenous mechanism of inactivation that involves a 
membrane transport system and at least two degradative enzymes [2]. From a 
physiological point of view and despite several efforts to define 
endocannabinoid ligands as emerging novel neurotransmitters, there is a 
general consensus that cannabinoid receptors and their ligands, rather than 
transmitters, function as neuromodulators [3]. Thus, by acting, for example, as 
retrograde messengers at various synapses, endocannabinoids participate in the 
control of processes such as memory and learning, appetite, emesis, 
nociception, certain motivational responses, and also in the control of 
movement [1-3]. The latter is exerted mainly by modulating the function of the 
basal ganglia, but also acting at the cerebellum [4-6].  
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Function of the cannabinoid signaling system in the 
basal ganglia 
 Endocannabinoids and their receptors, in particular the CB1 receptor 
subtype, are abundant in the basal ganglia in comparison with other brain 
structures [7-10]. Two basal ganglia structures, the globus pallidus and the 
substantia nigra which are strongly innervated by striatal projection neurons, 
deserve to be mentioned because of their abundancy in elements of the 
cannabinoid system [7-10]. The activation or blockade of CB1 receptors 
located in these structures produce important effects on the function controlled 
by the basal ganglia which are reflected in marked changes in different motor 
responses (for review, see [4,5]). However, the location of these receptors at 
different sites in the basal ganglia circuit may sometimes produce paradoxical 
effects (see [6] for a recent review). In general, cannabinoid agonists have 
powerful actions, mostly of inhibitory nature, on motor activity ([11-15]; for 
reviews see [5,6,16]), although there are differences in the magnitude and 
duration of their effects depending on their differences in receptor affinity, 
potency, and/or metabolic stability (see [6] for review). The behavioral 
consequences following the activation or blockade of CB1 receptors are 
certainly related to the capability of these receptors to influence the activity of 
a series of neurotransmitters that have been currently shown to be involved in 
the basal ganglia function (for reviews, see [4-6,16]). Finally, it is also 
important to note that cannabinoid receptors or other key proteins of the 
cannabinoid system appear to be significantly altered in different basal ganglia 
disorders, a phenomenon proved in human patients [5,6,17-21] or in different 
animal models for these diseases [21-26]. This opens the possibility for 
cannabinoid-based medicines to be used for the treatment of these disorders 
(see [6] for a recent review). The present chapter will address all of this 
previous pharmacological, biochemical, anatomical, and pathological 
evidence, trying to establish the bases that support the therapeutic potential of 
the cannabinoid system in basal ganglia disorders. 
 
Presence of elements of the cannabinoid system in the basal 
ganglia 
 As mentioned above, the identification and quantification of diverse 
elements of the cannabinoid signaling system in the basal ganglia have served 
as a way to demonstrate the importance of the role played by this system in the 
control of motor function (for a review see [5,6]). Thus, the use of 
autoradiographic techniques during the 90s demonstrated that the basal ganglia 
are among the brain structures containing the highest levels of both binding 
sites and mRNA expression for the CB1 receptor (for details, see [5,6]). In 
particular, the three nuclei recipient of striatal efferent outputs (globus pallidus,  
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entopeduncular nucleus, and substantia nigra pars reticulata in rodents; see 
details in Figure 1) contain high levels of receptor binding sites [7]. By 
contrast, CB1 receptor-mRNA transcripts were not detectable in these three 
nuclei, but they could be measured in the caudate-putamen ([8] and Figure 1). 
This particular distribution of binding sites and mRNA transcripts for the CB1 
receptor [7,8] is compatible with a possible presynaptic location of these 
receptors in striatal projection neurons [6], a fact that was corroborated by 
studying the changes in CB1 receptors produced by selective lesions of 
different subpopulations of striatal neurons [27]. More recently, the availability 
of selective CB1 receptor antibodies allowed a more precise analysis of the 
cellular distribution of this receptor subtype in the basal ganglia [9,28,29]. 
Thus, CB1 receptors are located in both striatonigral (the so-called “direct” 
striatal efferent pathway) and striatopallidal (the so-called “indirect” striatal 
efferent pathway) projection neurons, which are GABA-containing neurons. In  
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Figure 1.  Autoradiograms demonstrating the high concentrations of cannabinoid CB1 
receptors (binding, mRNA expression and activation of GTP-binding proteins) in the 
rat basal ganglia. 
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both  pathways,  CB1  receptors  are  co-expressed  with  other    markers, such as 
glutamic acid decarboxylase, prodynorphin, substance P, or proenkephalin, as 
well as D1 or D2 dopaminergic receptors [29]. In contrast, intrinsic striatal 
neurons, that contain somatostatin or acetylcholine, do not appear to contain 
CB1 receptors [29], although a recent study by Fusco and coworkers [28] has      
demonstrated immunoreactivity for this receptor subtype in some subclasses of 
striatal interneurons. Another subpopulation of CB1 receptors in the basal 
ganglia is located on subthalamopallidal and/or subthalamonigral gluta-
matergic terminals, as revealed by the presence of measurable levels of mRNA 
for this receptor in the subthalamic nucleus, together with the absence of 
detectable levels of cannabinoid receptor binding in that structure [8]. 
 The studies performed during the 90s indicated that CB2 receptors do not 
appear to be present in the healthy brain [30]. However, some recent studies 
have provided direct evidence of their presence in the healthy cerebellum 
[31,32], suggesting that this receptor subtype might also play a role in various 
cerebellar processes in normal conditions. These data have been recently 
corroborated by the identification of CB2 receptors in other brain regions of 
different species without neurological pathology [33,34], including 
unpublished data from our group that proved CB2 receptor immunoreactivity 
and mRNA expression in the rat striatum although possibly located in 
astrocytes rather than in neurons. This obviously points to a role for this 
receptor subtype in normal brain functions, including the control of basal 
ganglia activity. However, CB2 receptor function seems to be more important 
in response to different types of insults, including injury or inflammation, when 
they are significantly induced/upregulated in activated astrocytes or reactive 
microglia to control several events related to the protective and/or cytotoxic 
influences that the different glial cells exert on neuronal survival [35,36]. 
 
 The vanilloid TRPV1 receptor has been functionally related to the 
cannabinoid signaling system since certain endocannabinoids are able to act as 
endogenous ligands for this cation channel. Although TRPV1 receptors were 
primarily identified in pain-related areas, there is evidence indicating that 
TRPV1 receptors are also present in the basal ganglia circuitry colocalizing 
with tyrosine hydroxylase, which suggests that they are located in nigrostriatal 
dopaminergic neurons [37]. In fact, they are lowered by treatment with 6-
hydroxydopamine (6-OHDA) which degenerates dopaminergic neurons [38]. 
By contrast, TRPV1 receptor binding increased in the striatum of mice 
deficient in dopamine (DA) transporter [39]. This upregulation may be aimed 
at compensating the spontaneous hyperactivity exhibited by these mice and the 
low anandamide levels found in their striatum. In this respect, the 
administration of several inhibitors of endocannabinoid inactivation decreased 
the spontaneous hyperlocomotion by acting preferentially through TRPV1 
receptors [39]. As will be detailed below, the location of TRPV1 receptors in 
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nigrostriatal dopaminergic neurons provides an alternative for certain 
endocannabinoids to act through these receptors directly controlling DA 
synthesis and release [40], which would complete their classic action mediated 
by CB1 receptors directly controlling GABA and/or glutamate (GLU) function 
in the basal ganglia circuitry [5,6]. However, a recent double immuno-
histochemical study has shown that CB1 and TRPV1 receptors might colocalize 
in the caudate-putamen, the globus pallidus and the substantia nigra [41].  
 
 Anandamide and 2-arachidonoylglycerol, the two major endocannabinoid 
ligands, are also present in the basal ganglia in concentrations that are in 
general higher than those measured in the whole brain [10,42]. As for the 
density of CB1 receptors, the globus pallidus and the substantia nigra are the 
two basal ganglia that contain the highest levels of endocannabinoids [42]. 
Both endocannabinoids seem to be synthesized in the basal ganglia [6] 
although the phenotype of the nerve cells that produce these endocannabinoids 
is presently unknown. It is important to mention that, in the case of anandamide, 
the synthesis seems sensitive to DA, so that D2 receptors activated by DA 
released by nigrostriatal neurons would be associated with an enhancement of 
anandamide synthesis aimed at serving as an inhibitory feedback mechanism 
that counteracts DA-induced facilitation of psychomotor activity [43].  
 
 Other elements of the cannabinoid signaling system that have been identified, 
in some cases at high concentrations, in the basal ganglia are: (i) the 
endocannabinoid transporter, although the evidence for this protein is indirect and 
obtained mainly from pharmacological studies ([44-47]; for review see [6]), (ii) the 
enzyme fatty acid amide hydrolase (FAAH), which is  involved in the degradation 
of anandamide [48,49], and (iii) the enzyme monoacylglycerol-lipase, which is 
involved in the degradation of 2-arachidonoylglycerol (see [50] for a review). 
However, these two enzymes accept as substrates various N-acylethanolamines or 
mono-acylglycerols, respectively, so lacking the necessary specificity to be used as 
selective markers of cannabinoid transmission. 
 
Control of motor activity by cannabinoids 
 The abundancy of elements of the cannabinoid signaling system in the 
basal ganglia suggests an important role for this system in the control of 
neurobiological function(s) that reside(s) in these structures, namely, the 
control of motor function. This seems to be the case since the evidence 
published so far indicates that: (i) the consumption by humans of psychoactive 
cannabinoids, such as those present in marijuana or other Cannabis sativa 
preparations, which act by activating CB1 receptors, produce a series of motor 
effects, most of them of inhibitory nature (for review see [51]), (ii) the direct  
activation of CB1 receptors with plant-derived, synthetic, or endogenous 
agonists produced dose-dependent impairments in a variety of motor tests 
(open-field, ring test, actimeter, rotarod) in laboratory animals [11-15,52-59], 
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and (iii) the administration of inhibitors of endocannabinoid inactivation, so-
called indirect agonists, which act by prolonging the action of endocanna- 
binoids at their receptors, mainly the CB1 receptor subtype, also inhibited 
movement in laboratory animals ([44-47], see [6] for a recent review). By contrast, 
a few studies that used administration of very low doses of anandamide, ∆9-
tetrahydrocannabinol (∆9-THC), or other cannabinoids reported hyperkinetic 
effects of these agonists in mice [60] and rats [61] in comparison with the 
hypokinetic effects reported when higher doses were used (see [5,6] for review). 
 
 It is important to note at this point that the above evidence was obtained 
with compounds that act both, directly or indirectly, and selectively or non-
selectively, at the CB1 receptor, thus stressing the relevance of this 
cannabinoid receptor subtype in the control of basal ganglia function in 
concordance with its abundant presence in this circuitry. In support of this 
notion, the motor effects of most cannabinoid agonists were usually prevented 
by SR141716, a selective CB1 receptor antagonist ([60,62], for a review, see 
[4]), which, due to its inverse agonist properties, was also able to cause 
hyperlocomotion by itself [63]. However, there is pharmacological evidence 
that certain cannabinoids might have additional targets which affect motor 
function. Thus, the motor effects of anandamide or other eicosanoid-based 
cannabinoid agonists, such as AM404, might be originated by their capability 
to bind and activate vanilloid TRPV1 receptors, since these effects were 
reversed by capsazepine but not by SR141716 [25,40,64]. In concordance with 
this observation, the activation of TRPV1 receptor by agonists, such as 
capsaicin, produced motor inhibition [62]. The recent detection of TRPV1 
receptors in the basal ganglia [37] supports this hypothesis. 
 
Interactions with classic transmitters acting at the basal ganglia 
 The motor effects following the activation or the inhibition of the 
cannabinoid signaling system likely depend on the control exerted by this 
system on the activity of those neurotransmitters that have been involved in the 
control of basal ganglia function, in particular, DA, GABA and GLU (Figure 
2). The location of CB1 receptors in several GABA- or GLU-containing 
neuronal subpopulations in the basal ganglia, as well as the recent 
identification of TRPV1 receptors in nigrostriatal dopaminergic neurons (see 
[6] for a recent review), enables endocannabinoids to directly control the 
function of GABAergic, glutamatergic or dopaminergic transmissions. Due to 
the  preferent  presynaptic  location      of  the  receptors,  they seem to participate 
mainly in the control of presynaptic events, such as synthesis, release, or 
reuptake for these neurotransmitters (see [6] for a recent review). 
  The supporting evidence that GABAergic transmission in the basal ganglia 
mediates the motor effects of cannabinoids is based on (i)  anatomical (i.e. location 
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Figure 2. Diagram summarizing the different interactions proposed for the cannabinoid 
system with classic neurotransmitters acting at the basal ganglia. 
 
location of CB1 receptors in striatal projection neurons [8,27]), (ii) 
pharmacological (i.e. administration of cannabinoids combined with agonists 
or antagonists for GABA-A or –B receptors [13,52,65]), (iii) 
electrophysiological (i.e. monitoring the inhibitory currents after the 
application of cannabinoids in vivo [66,67]), and (iv) neurochemical (i.e. 
analysis of neurotransmitter synthesis, release and reuptake in vivo or in 
GABA-containing synaptic preparations [25,68,69]) data. All this evidence is 
compatible with an enhancement of GABA-mediated transmission by 
endocannabinoids in the globus pallidus and the substantia nigra, which 
concurs with the hypokinetic action of these compounds (see [6] for a recent 
review). However, there are some studies showing inhibition rather than 
stimulation of GABAergic inputs by cannabinoid agonists [70-72]. 
 In a similar way to GABA, there is also evidence to show that 
cannabinoids also exert a direct action on GLU-releasing neurons in the basal 
ganglia. This is based on the anatomical demonstration that CB1 receptors are 
located in subthalamonigral glutamatergic neurons [8] and their activation inhibits 
movement [73]. Also, electrophysiological evidence shows that cannabinoid 
agonists modify the activity of pallidal and nigral neurons through inhibiting GLU 
release from the terminals projecting from the subthalamic nucleus [74,75]. There 
is also increasing evidence indicating that CB1 receptors may be also located in 
cortical afferents projecting to the caudate-putamen which are glutamatergic, since 
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the activation of these receptors results in an inhibition of GLU release from these 
terminals, this effect being also blocked by SR141716 [76]. 
 DA transmission in the basal ganglia is also inhibited by cannabinoid agonists, 
as has been revealed by several neurochemical analyses ([14,15,44,77]; see [78] for 
a recent review). This effect is consistent with the ability of cannabinoid agonists to 
produce hypokinesia (see above), and also with the observations that cannabinoids 
potentiated reserpine induced hypokinesia [55], while reducing amphetamine-
induced hyperactivity [56]. However, the effects of cannabinoid agonists on DA 
transmission were frequently small and transient. This is possibly due to the fact 
that, contrary to the case of GABA- and GLU-containing neurons, CB1 receptors 
are not located on DA-containing neurons in the basal ganglia in the adult brain 
[6], so that the DA effects of classic cannabinoids (plant-derived and analogs) 
would be originated indirectly through their effects on GABAergic transmission 
[68,69]. However, it is also possible that the effects of cannabinoids on DA 
transmission may be produced by an interaction at the level of G protein/adenylyl 
cyclase signal transduction mechanisms shared by both CB1 and D1/D2 
dopaminergic receptors [42,79]. The colocalization of CB1 receptors with D1 
receptors in striatal neurons projecting to the substantia nigra, or with D2 receptors 
in those projecting to the globus pallidus (see [6] for review), makes this type of 
postreceptor interaction possible. In addition and in contrast with classic 
cannabinoids, certain agonists, such as anandamide and some analogs, would also 
be able to directly influence dopaminergic transmission through the activation of 
vanilloid TRPV1 receptors. These have been identified in DA-containing neurons 
in the basal ganglia [37] and their activation by anandamide decreased motor 
activity via a DA-lowering effect exerted directly on these neurons [40]. Classic 
cannabinoids, such as ∆9-THC, that do not bind to vanilloid-like receptors were not 
able to produce this effect [40]. 
 
Therapeutic potential of the cannabinoid system in 
basal ganglia disorders 
 The above data relate the cannabinoid system to the control of basal 
ganglia function. Studies that will be presented below demonstrate the 
occurrence of changes in different elements of this system, in particular the 
CB1 receptor, in the postmortem basal ganglia of humans affected by several 
basal ganglia disorders and also in animal models of these disorders (for 
review, see [6]). Based on these two ideas, one may hypothesize that 
compounds active in cannabinoid transmission might be useful in alleviating 
motor symptoms [6,78] and delaying/arresting the degeneration of basal 
ganglia [36,80] in both hyper- and hypokinetic disorders. Among these 
disorders, Parkinson’s disease (PD) and Huntington's disease (HD) are the two 
diseases  directly  related to the control of movement that have attracted most 
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interest in terms of a potential therapeutic application of cannabinoids (for 
review see [6,36]). Another interesting related disorder in which cannabinoids 
might be effective is Gilles de la Tourette’s syndrome (TS) ([81] for a review). 
Finally, other diseases not directly related to a degeneration of basal ganglia 
structures but exhibiting strong motor symptoms, such as Alzheimer’s disease 
(AD) (see [82] for a review) or multiple sclerosis (MS) (see [83] for a review), 
have also been examined for a potential therapeutic application of 
cannabinoid-based compounds. Most of the data presented in this review will 
concentrate on HD and PD as the most representative examples of therapeutic 
application of cannabinoids in basal ganglia degeneration, although some 
additional comments on other diseases are also included. 
 
Changes in the cannabinoid signaling system in basal ganglia 
disorders 
 Assuming that the activation of the cannabinoid system increases GABA 
transmission in the basal ganglia, consequently reducing movement, it would be 
expected for this system to become progressively hypofunctional in HD, the 
most representative hyperkinetic disorder [84]. This was confirmed by analyzing 
postmortem tissue from patients where an almost complete disappearance of CB1 
receptors could be observed in different structures of the basal ganglia 
[17,18,20]. Similar results were obtained in different types of animal models for 
this disease, where the reductions affected CB1 receptors [24-26,85,86] but also 
endocannabinoid levels [87]. This loss of CB1 receptors is representative of the 
pattern of neuronal loss observed in HD that predominantly affects CB1 receptor-
containing medium-spiny GABAergic neurons [27,29], so a priori it could be a 
mere side effect caused by the progressive and selective destruction of striatal 
GABAergic projection neurons where these receptors are located. However, an 
interesting aspect is that the reduction of CB1 receptors seems to occur in 
advance of other receptor losses and even before the appearance of major HD 
symptomatology, when the incidence of cell death is still low [18], thus 
indicating that these losses might be involved in the pathogenesis itself or in the 
progression of striatal degeneration (see [84] for review). This concurs with the 
data obtained in various transgenic mouse models that express mutated forms of 
the human huntingtin gene, where the reductions of CB1 receptors in the basal 
ganglia already occur with neuronal malfunctioning but in absence of cell death 
[85,86]. In the same line, reductions in CB1 receptor function (G-protein 
activation by WIN55,212-2), in the absence of changes in binding and mRNA 
levels for this receptor, have been documented at very early stages of striatal 
degeneration caused by inhibition of mitochondrial complex II [88]. 
Collectively, these observations seem to indicate that the losses or the 
malfunctioning of  CB1 receptors in specific neuronal subpopulations of  the basal  
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ganglia might render these neurons more vulnerable to different cytotoxic stimuli 
that frequently operate in HD (oxidative stress, excitotoxicity, inflammation), 
suggesting that the activation of these receptors may be used as a neuroprotectant 
strategy in this disease (see below). In support of this hypothesis, van der Stelt 
and coworkers recently suggested that the malfunctioning of the cannabinoid 
system may be a signal to trigger an unbalance in GLU homeostasis and initiate 
excitotoxicity (see [89] for review), although this remains to be demonstrated.  
 By contrast, hypokinetic disorders, such as PD, should be characterized by 
an overactivity of the cannabinoid signaling system in the basal ganglia, a fact 
already proved in patients [19,21] and animal models of this disease [21-
23,41,90-92], and compatible with the hypokinesia that characterizes this 
disease. Compared with HD, much less data exist on the status of CB1 
receptors in the postmortem basal ganglia of humans affected by PD. We 
recently found that CB1 receptor binding and signaling were significantly 
increased in the basal ganglia of patients [21]. The same happens with 
endocannabinoid levels in the cerebrospinal fluid (CSF) of patients [19] and in 
different basal ganglia in animal models of PD [41,90,92]. Interestingly, these 
increases were reversed by treatment with levodopa [91], thus suggesting the 
existence of a marked imbalance between DA and endocannabinoids in the 
basal ganglia in PD (see [6] for a recent review). As in HD, the upregulation of 
CB1 receptors might also be an early event related to the pathogenesis of PD. 
This is supported by data obtained from individuals affected by incidental 
Lewy body disease, an early and presymptomatic phase of PD [21], and also in 
PARK2 knockout mice that only develop neuronal dysfunction but not 
neuronal death [93].  
 There is no information on the status of the cannabinoid signaling system 
in other diseases where alterations in the basal ganglia function have been 
documented. This is the case in tardive dyskinesia, TS, dystonia, and others. 
However, as will be described below, cannabinoid-related medicines may be 
useful as symptom-alleviating agents or as neuroprotectant substances in these 
disorders (see [6,36] for review). Little information exists for other disorders 
such as MS and AD. Both diseases are not originated by a primary 
degeneration of the basal ganglia, but in both cases, the primary cause of these 
diseases originates secondarily in the malfunctioning of the basal ganglia 
circuitry and the appearance of motor extrapyramidal signs. For instance, some 
studies have recently examined the status of brain cannabinoid transmission in 
animal models of multiple sclerosis [94-97] and found alterations restricted mainly 
to the basal ganglia structures [95-97], in particular in the case of CB1 receptors 
[95,97], which is consistent with the fact that motor deterioration is one of the most 
prominent neurological signs in this disease. By contrast, to date there is no published 
data on CB1 and CB2 receptors or endocannabinoid levels in the postmortem brain or 
in  biological fluids of  patients  with MS, although  several  laboratories have 
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presented the first evidence in abstract form (see 2006 annual meeting of ICRS). 
The case of AD, however, is possibly the opposite to that of MS because most of 
the data on the status of cannabinoid transmission in this disease come from studies 
in postmortem human tissue, whereas confirmatory studies in animal models are 
still pending. Thus, the analysis of CB1 receptors in postmortem brain regions of 
patients affected by this disease revealed a significant loss in the basal ganglia but 
not in other regions [98]. However, it is important to mention that the authors 
considered that their results reflected more an influence of aging than an effect 
selectively associated with the pathology characteristic of AD [98]. Also using 
postmortem tissue from Alzheimer’s patients, Benito et al. [35] reported the 
induction of CB2 receptors in activated microglia that surround senile plaques. This 
would suggest a role for this receptor subtype in the pathogenesis of this disease 
and a therapeutic potential for compounds that selectively target this receptor (see 
[36] for details). 
 
Alleviation of motor symptoms by cannabinoids in basal 
ganglia disorders 
 As mentioned above, the hypofunctionality of the cannabinoid system 
reported for HD might contribute to some extent to the hyperkinesia typical of this 
disorder. This would also support a therapeutic usefulness of cannabinoid agonists 
for alleviating hyperkinetic symptoms (for review see [6,84]), which might be 
particularly relevant in a disorder where the therapeutic outcome is still poor. 
However, the few clinical trials developed so far indicate that the administration of 
plant-derived cannabinoids [4], or some of their synthetic analogs [99], increase 
choreic movements in HD patients. It is possible that this is related to the lack of 
TRPV1 receptor activity of the cannabinoid agonists used in those clinical trials, 
since recent studies carried out in our laboratory in a rat model of HD revealed that 
only those cannabinoid-based compounds having an additional profile as TRPV1 
receptor agonists were really effective in alleviating hyperkinetic signs [25,64]. 
This was the case for AM404, which, in addition to its ability to block the 
endocannabinoid transporter, also exhibited direct activity at the TRPV1 receptor. 
This compound was able to reduce hyperkinesia and to induce recovery from 
GABAergic and dopaminergic deficits in a rat model of HD [25,64], while direct 
agonists of CB1 receptors, such as CP 55,940, only produced very modest effects 
[64]. Other inhibitors of the endocannabinoid inactivation, that are not active at the 
TRPV1 receptor, such as VDM11 or AM374, did not have any antihyperkinetic 
action in a rat model of HD [64], whereas UCM707, the most potent inhibitor to 
date, only produced modest effects [100]. Therefore, our data suggest that TRPV1 
receptors alone, or better in combination with CB1 receptors, might represent novel 
targets through which the hyperkinetic symptoms of HD could be alleviated. 
Possibly, the best option might be to develop “hybrid” compounds with the dual 
capability of  activating both     TRPV1 and CB1 receptors, although the relative 
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contribution made by each of these targets is likely to change during the course of 
the disease due to a progressive loss of CB1 receptors without any concomitant loss 
of TRPV1 receptors (see [6,84] for a review). 
 Cannabinoid-based compounds might also be useful as symptom-alleviating 
agents in PD. In this case, the overactivity found in the cannabinoid transmission 
in the basal ganglia in PD supports the idea that CB1 receptor antagonists, rather 
than agonists, might be the most valuable compounds for alleviating 
bradykinesia in PD [42,101,102] or for reducing the development of dyskinesia 
caused by prolonged replacement therapy with levodopa [103]. However, CB1 
receptor agonists have also been reported to have therapeutic value in PD in 
certain circumstances, for instance: (i) by interacting with dopaminergic agonists 
to improve motor impairments [104,105], (ii) by reducing tremor associated with 
an overactivity of the subthalamic nucleus [16,105] although the only clinical 
trial developed so far led to negative results [106], (iii) by delaying levodopa-
induced dyskinesia [107], and (iv) by delaying/arresting the progression of nigral 
degeneration (see [36] and below). Because of the hypokinetic profile of 
cannabinoid agonists, it is unlikely that these compounds might be, however, 
useful for alleviating bradykinesia, which is the major symptom in most PD 
patients, being the blockade of CB1 receptors  a better strategy for reducing this 
symptom (see [6] for review) and levodopa-induced dyskinesia [92,103]. In 
theory, CB1 receptor blockade would prevent the excessive inhibition of GABA 
uptake produced by the increased activation of CB1 receptors in striatal 
projection neurons [68,69], thus allowing a faster removal of this inhibitory 
neurotransmitter from the synaptic cleft, which would reduce hypokinesia. 
Despite this evidence, the first pharmacological studies that have examined the 
capability of rimonabant (SR141716) to reduce hypokinesia in animal models of 
PD have yielded conflicting results [42,108] and no response was found in 
patients in the only clinical trial developed so far [109]. It is possible that the 
blockade of CB1 receptors might be effective only in special circumstances, such 
as: (i) low doses of rimonabant, (ii) very advanced phases of the disease, or (iii) 
patients with a poor response to classic levodopa treatment, as recent studies 
have claimed [101,102]. If this were the case, it would be possible to have an 
antiparkinsonian agent for conditions in which classic therapy generally fails. 
 
 Cannabinoids might be also of interest for the alleviation of motor symptoms 
in other disorders affecting the basal ganglia directly or indirectly. For example, 
cannabinoids have antidystonic effects demonstrated in humans [110] and animal 
models [111,112]. Plant-derived cannabinoids have also been reported to reduce 
tics and also to improve behavioral problems in patients with TS [4,81,113-116]. 
Studies in laboratory animals have convincingly demonstrated that both direct and 
indirect cannabinoid receptor agonists are useful in alleviating motor-related 
symptoms in multiple sclerosis, such as spasticity, tremor, dystonia, and              others (for 
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reviews see [83,117]). These effects seem to be preferentially mediated by CB1 
receptors [118]. In line with these data, a clinical trial, recently completed in the 
UK, has explored the efficacy of cannabinoid-based medicines in MS, showing 
some beneficial effects on specific symptoms [119,120]. 
 
Neuroprotection with cannabinoids in basal ganglia disorders 
 In addition to their capability to alleviate specific symptoms in basal 
ganglia disorders, cannabinoids might have an additional therapeutic value 
because of their neuroprotective properties [36]. Cannabinoids are capable of 
reducing excitotoxicity, calcium influx and oxidative injury (see [36,80] for 
review). They are also able to decrease inflammation by acting on glial 
processes that regulate neuronal survival, and to restore blood supply to the 
injured area by reducing the vasoconstriction produced by several 
endothelium-derived factors [36]. Through one or more of these processes, 
cannabinoids may provide neuroprotection in conditions of acute 
neurodegeneration, such as that occurring in traumatic injury or ischemic 
episodes [121], but also in chronic diseases, such as those initially caused by 
inflammatory processes, like MS [122], or those related to cognitive 
deterioration, such as AD [36,81], or those affecting motor control or 
performance, such as amyotrophic lateral sclerosis, PD and HD [36]. Here, we 
will concentrate on these two last neurodegenerative diseases.  
 
 As regards to HD, we and other laboratories have recently provided 
preclinical supporting evidence (see above sections) that cannabinoids might 
be used as neuroprotectant agents in patients (see [36] for review). The 
rationale for this hypothesis is based on the idea that the cannabinoid system 
experiences important changes during the onset and progression of HD [84]. 
Thus, as mentioned above, CB1 receptor losses and/or dysfunction in the basal 
ganglia would be very early events that would take place before the appearance 
of major neuropathological signs and when cell death has not occurred yet or is 
minimal (see above sections). In addition, CB2 receptors are induced/upregulated 
when cell death progresses (see [123] for review). In this context, compounds 
targeting selectively CB1 and/or CB2 receptors would be expected to be 
effective in attenuating striatal degeneration in HD (see above sections). Thus, 
Pintor et al. [124] reported that CB1 receptor agonists were able to reduce the 
striatal damage in rats lesioned with quinolinic acid, a neurotoxin able to 
reproduce an excitotoxic episode. Therefore, one may assume that the 
activation of CB1 receptors may provide neuroprotection against the 
excitotoxic death that occurs in HD. For these authors [124], HD patients 
would experience a decrease in CB1 receptor-mediated inhibition of GLU 
release, thus resulting in excitotoxicity (see above sections). This can be 
hypothesized from the data that indicate that HD patients have low levels of 
both CB1 receptors and their ligands in the striatum, so that a recovery of CB1 
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receptor function might be effective in reducing striatal damage [124]. 
However, there are other studies that indicate that cannabinoids may also be 
effective against other types of neurotoxic events that also operate in HD. 
Thus, we observed that the administration of the agonist phytocannabinoid ∆9-
THC reduced the degeneration of striatal GABA projection neurons caused by 
mitochondrial complex II inhibition with 3-nitropropionic acid in rats, a HD 
model where neuronal death progresses through non-apoptotic mechanisms 
[88]. The basis for this neuroprotective effect might be the capability of ∆9-
THC to elevate cannabinoid receptor signaling in the basal ganglia, which, as 
mentioned in the study conducted by Pintor et al. [124], is concordant with the 
observation that cannabinoid CB1 receptors and their ligands are impaired in 
several structures of the basal ganglia in HD patients [17,18,20] and also in 
animal models of this disease [24-26,88]. Therefore, it might be a priori 
postulated that the neuroprotective effect of ∆9-THC in this HD model is also 
mediated by the activation of CB1 receptors. However, ∆9-THC is a partial 
agonist of CB1 receptors, so the implication of other different mechanisms 
(i.e., antioxidant, vascular and/or antiinflammatory effects; see [36] for review) 
might also be expected. In fact, we have preliminary and unpublished data 
indicating that another phytocannabinoid, cannabidiol, which does not bind to 
cannabinoid receptors but that exhibits an important antioxidant potential, was 
neuroprotectant to the same extent as ∆9-THC in this rat model of HD 
(Sagredo et al., unpublished results). This suggests that antioxidant properties 
of phytocannabinoids would possibly be the key mechanism allowing for the 
neuroprotective potential of these compounds against the non-apoptotic death 
of striatal neurons. By contrast, we have also unpublished data indicating that 
the activation of CB2 receptors, presumably located on reactive microglia 
recruited at the lesioned striatum, might reduce the cytotoxicity exerted by these 
cells (i.e. generation of nitric oxide, proinflammatory cytokines, and reactive 
oxygen species) on striatal neurons in rats lesioned with malonate, a model of HD 
where neuronal death progresses by activation of the apoptotic machinery (Sagredo 
et al., unpublished results). Therefore, the three key mechanisms that enable 
cannabinoid compounds to provide neuroprotection in HD would be: (i) their 
capability to reduce GLU-toxicity mediated by CB1 receptors, (ii) their 
cannabinoid receptor-independent antioxidant properties, and/or (iii) their 
activity at the CB2 receptor to control microglial influence on neurons. Clinical 
trials to validate these options are going to be conducted soon. 
 We have also provided preclinical evidence that certain cannabinoid agonists 
may also be neuroprotectant in PD (see [36] for review), although the hypokinetic 
profile of most cannabinoid agonists may represent a disadvantage, since they might 
acutely enhance rather than reduce motor symptoms in this disease, as proved in 
several clinical trials (see [4,36] for review). We found that several plant-derived 
cannabinoids were able to reduce the degeneration of nigrostriatal dopaminergic 
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neurons generated by 6-OHDA [38]. The fact that this effect was observed for ∆9-
THC, which is able to bind both CB1 and CB2 receptors, but also for cannabidiol, 
which does not bind either cannabinoid receptor subtypes suggested that it is likely 
originated by the antioxidant and cannabinoid-receptor independent properties of 
both plant-derived cannabinoids. This has been confirmed by examining the potential 
of other compounds with antioxidant properties such as AM404, in the same PD 
model [125]. However, other additional mechanisms seem also to be active in PD. 
Thus, we also found that HU-210, a non-selective cannabinoid receptor agonist, 
increased neuronal survival against the in vitro neurotoxicity of 6-OHDA [38]. HU-
210 is also antioxidant, but, in our study [38], it acted through increasing the trophic 
support exerted by glial cells on neurons, an effect that might be presumably CB1 or 
CB2 receptor-mediated. Recent evidence indicate that, it is most likely to be CB2 
receptor-mediated, since HU-308, a selective CB2 receptor agonist, was also able to 
provide some degree of neuroprotection in hemiparkinsonian rats [125]. Therefore, 
the two key mechanisms that enable cannabinoids to provide neuroprotection in PD 
would be their cannabinoid receptor-independent antioxidant properties and their 
affinity at the CB2 receptors. Clinical trials should also validate these two options in 
PD patients. 
 
Concluding remarks and future perspectives 
 The studies reviewed here are all concordant with the view that the 
cannabinoid signaling system plays a key function in the control of movement. 
This view is supported by large anatomical, electrophysiological, 
pharmacological and biochemical evidence. We have also shown that the 
cannabinoid system becomes impaired in different disorders that affect directly 
or indirectly the basal ganglia. This provides the basis for the development of 
novel pharmacotherapies with compounds that selectively target specific 
elements of the cannabinoid system. These treatments might cover not only the 
alleviation of specific symptoms (i.e. hyperkinesia in HD, tremor and 
bradykinesia in PD) but also the delay/arrest of the disease progression due to 
the neuroprotectant properties described for certain cannabinoids. However, 
most of the studies that have examined the therapeutic potential of these 
compounds in motor disorders have been conducted in animal models whereas 
the number of clinical trials is still limited. The importance of this intercellular 
signaling system demands further clinical investigation, as well as the development 
of novel compounds with more selectivity for the different proteins (CB1 or CB2 
receptors, TRPV1 receptor, endocannabinoid transporter, degradative enzymes) 
that constitute the cannabinoid system, this in an attempt to minimize the frequent 
side effects observed when classic cannabinoids are used in patients. 
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